Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction

Area of Science:

• Cardiology
• Biomarker Research
• Heart Failure Management

Background:

• The GUIDE-IT trial investigated biomarker-guided therapy for heart failure (HF).
• A strategy using NT-proBNP to guide therapy was compared to guideline-directed medical therapy (GDMT) alone.
• The trial found no superiority of biomarker-guided therapy over GDMT alone.

Purpose of the Study:

• To evaluate the prognostic significance of NT-proBNP changes after HF therapy intensification.
• To assess NT-proBNP levels relative to the GUIDE-IT trial's goal of 1,000 pg/ml.
• To correlate NT-proBNP reduction with clinical outcomes and quality of life.

Main Methods:

• Analysis of 638 patients with available NT-proBNP at 90 days post-randomization.
• Assessment of cardiovascular death, HF hospitalization, and all-cause mortality rates.
• Evaluation of Kansas City Cardiomyopathy Questionnaire (KCCQ) scores.

Main Results:

• 198 patients (31.0%) achieved NT-proBNP ≤1,000 pg/ml by 90 days.
• Achieving NT-proBNP ≤1,000 pg/ml was linked to reduced HF hospitalization/CV death and all-cause mortality (p < 0.001).
• Lower NT-proBNP levels correlated with better KCCQ scores (p = 0.02).

Conclusions:

• Reduced NT-proBNP levels to ≤1,000 pg/ml during GDMT indicate better outcomes in HF patients.
• These findings provide context for the GUIDE-IT trial's results.
• NT-proBNP serves as a valuable prognostic marker in heart failure management.